Proteolix: A 'Me-Too' Success

by Larry Lasky


In an industry rife with failures, Proteolix, a biotechnology company, was a rare success. The Proteolix case provides a compelling example of a biotech company that has chosen a 'me-too' strategy, a less risky strategy than the strategy of discovering a drug for a novel target. However, even me-too drug strategies in the biotech industry face an uphill battle. The protagonist, Susan Molineaux, along with her team, faced many challenges along the way and the case study provides students with a map of some of her key decisions at important points in the company's history. The case study asks students to evaluate Molineaux's and her team's decisions and to identify the company's drivers of success. The Proteolix case also allows students to understand the biotechnology industry, its unique challenges, and the particular challenges facing a me-too drug company that is attempting to dislodge a drug to treat life-threatening indications.


Details

Pub Date: Jul 31, 2012

Discipline: Entrepreneurship

Subjects: Startup, Corporate strategy, Start-ups, Growth strategy

Product #: B5719-PDF-ENG

Industry: Biotechnology,Venture capital

Geography: United States, California

Length: 14 page(s)

California Management Review

Berkeley-Haas's Premier Management Journal

Published at Berkeley Haas for more than sixty years, California Management Review seeks to share knowledge that challenges convention and shows a better way of doing business.

Learn more
Follow Us